Cargando…
Claudin-1, A Double-Edged Sword in Cancer
Claudins, a group of membrane proteins involved in the formation of tight junctions, are mainly found in endothelial or epithelial cells. These proteins have attracted much attention in recent years and have been implicated and studied in a multitude of diseases. Claudins not only regulate paracellu...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7013445/ https://www.ncbi.nlm.nih.gov/pubmed/31952355 http://dx.doi.org/10.3390/ijms21020569 |
_version_ | 1783496408491360256 |
---|---|
author | Bhat, Ajaz A. Syed, Najeeb Therachiyil, Lubna Nisar, Sabah Hashem, Sheema Macha, Muzafar A. Yadav, Santosh K. Krishnankutty, Roopesh Muralitharan, Shanmugakonar Al-Naemi, Hamda Bagga, Puneet Reddy, Ravinder Dhawan, Punita Akobeng, Anthony Uddin, Shahab Frenneaux, Michael P. El-Rifai, Wael Haris, Mohammad |
author_facet | Bhat, Ajaz A. Syed, Najeeb Therachiyil, Lubna Nisar, Sabah Hashem, Sheema Macha, Muzafar A. Yadav, Santosh K. Krishnankutty, Roopesh Muralitharan, Shanmugakonar Al-Naemi, Hamda Bagga, Puneet Reddy, Ravinder Dhawan, Punita Akobeng, Anthony Uddin, Shahab Frenneaux, Michael P. El-Rifai, Wael Haris, Mohammad |
author_sort | Bhat, Ajaz A. |
collection | PubMed |
description | Claudins, a group of membrane proteins involved in the formation of tight junctions, are mainly found in endothelial or epithelial cells. These proteins have attracted much attention in recent years and have been implicated and studied in a multitude of diseases. Claudins not only regulate paracellular transepithelial/transendothelial transport but are also critical for cell growth and differentiation. Not only tissue-specific but the differential expression in malignant tumors is also the focus of claudin-related research. In addition to up- or down-regulation, claudin proteins also undergo delocalization, which plays a vital role in tumor invasion and aggressiveness. Claudin (CLDN)-1 is the most-studied claudin in cancers and to date, its role as either a tumor promoter or suppressor (or both) is not established. In some cancers, lower expression of CLDN-1 is shown to be associated with cancer progression and invasion, while in others, loss of CLDN-1 improves the patient survival. Another topic of discussion regarding the significance of CLDN-1 is its localization (nuclear or cytoplasmic vs perijunctional) in diseased states. This article reviews the evidence regarding CLDN-1 in cancers either as a tumor promoter or suppressor from the literature and we also review the literature regarding the pattern of CLDN-1 distribution in different cancers, focusing on whether this localization is associated with tumor aggressiveness. Furthermore, we utilized expression data from The Cancer Genome Atlas (TCGA) to investigate the association between CLDN-1 expression and overall survival (OS) in different cancer types. We also used TCGA data to compare CLDN-1 expression in normal and tumor tissues. Additionally, a pathway interaction analysis was performed to investigate the interaction of CLDN-1 with other proteins and as a future therapeutic target. |
format | Online Article Text |
id | pubmed-7013445 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-70134452020-03-09 Claudin-1, A Double-Edged Sword in Cancer Bhat, Ajaz A. Syed, Najeeb Therachiyil, Lubna Nisar, Sabah Hashem, Sheema Macha, Muzafar A. Yadav, Santosh K. Krishnankutty, Roopesh Muralitharan, Shanmugakonar Al-Naemi, Hamda Bagga, Puneet Reddy, Ravinder Dhawan, Punita Akobeng, Anthony Uddin, Shahab Frenneaux, Michael P. El-Rifai, Wael Haris, Mohammad Int J Mol Sci Review Claudins, a group of membrane proteins involved in the formation of tight junctions, are mainly found in endothelial or epithelial cells. These proteins have attracted much attention in recent years and have been implicated and studied in a multitude of diseases. Claudins not only regulate paracellular transepithelial/transendothelial transport but are also critical for cell growth and differentiation. Not only tissue-specific but the differential expression in malignant tumors is also the focus of claudin-related research. In addition to up- or down-regulation, claudin proteins also undergo delocalization, which plays a vital role in tumor invasion and aggressiveness. Claudin (CLDN)-1 is the most-studied claudin in cancers and to date, its role as either a tumor promoter or suppressor (or both) is not established. In some cancers, lower expression of CLDN-1 is shown to be associated with cancer progression and invasion, while in others, loss of CLDN-1 improves the patient survival. Another topic of discussion regarding the significance of CLDN-1 is its localization (nuclear or cytoplasmic vs perijunctional) in diseased states. This article reviews the evidence regarding CLDN-1 in cancers either as a tumor promoter or suppressor from the literature and we also review the literature regarding the pattern of CLDN-1 distribution in different cancers, focusing on whether this localization is associated with tumor aggressiveness. Furthermore, we utilized expression data from The Cancer Genome Atlas (TCGA) to investigate the association between CLDN-1 expression and overall survival (OS) in different cancer types. We also used TCGA data to compare CLDN-1 expression in normal and tumor tissues. Additionally, a pathway interaction analysis was performed to investigate the interaction of CLDN-1 with other proteins and as a future therapeutic target. MDPI 2020-01-15 /pmc/articles/PMC7013445/ /pubmed/31952355 http://dx.doi.org/10.3390/ijms21020569 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Bhat, Ajaz A. Syed, Najeeb Therachiyil, Lubna Nisar, Sabah Hashem, Sheema Macha, Muzafar A. Yadav, Santosh K. Krishnankutty, Roopesh Muralitharan, Shanmugakonar Al-Naemi, Hamda Bagga, Puneet Reddy, Ravinder Dhawan, Punita Akobeng, Anthony Uddin, Shahab Frenneaux, Michael P. El-Rifai, Wael Haris, Mohammad Claudin-1, A Double-Edged Sword in Cancer |
title | Claudin-1, A Double-Edged Sword in Cancer |
title_full | Claudin-1, A Double-Edged Sword in Cancer |
title_fullStr | Claudin-1, A Double-Edged Sword in Cancer |
title_full_unstemmed | Claudin-1, A Double-Edged Sword in Cancer |
title_short | Claudin-1, A Double-Edged Sword in Cancer |
title_sort | claudin-1, a double-edged sword in cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7013445/ https://www.ncbi.nlm.nih.gov/pubmed/31952355 http://dx.doi.org/10.3390/ijms21020569 |
work_keys_str_mv | AT bhatajaza claudin1adoubleedgedswordincancer AT syednajeeb claudin1adoubleedgedswordincancer AT therachiyillubna claudin1adoubleedgedswordincancer AT nisarsabah claudin1adoubleedgedswordincancer AT hashemsheema claudin1adoubleedgedswordincancer AT machamuzafara claudin1adoubleedgedswordincancer AT yadavsantoshk claudin1adoubleedgedswordincancer AT krishnankuttyroopesh claudin1adoubleedgedswordincancer AT muralitharanshanmugakonar claudin1adoubleedgedswordincancer AT alnaemihamda claudin1adoubleedgedswordincancer AT baggapuneet claudin1adoubleedgedswordincancer AT reddyravinder claudin1adoubleedgedswordincancer AT dhawanpunita claudin1adoubleedgedswordincancer AT akobenganthony claudin1adoubleedgedswordincancer AT uddinshahab claudin1adoubleedgedswordincancer AT frenneauxmichaelp claudin1adoubleedgedswordincancer AT elrifaiwael claudin1adoubleedgedswordincancer AT harismohammad claudin1adoubleedgedswordincancer |